Repligen (RGEN) Continues Higher on Strong RG3039 Phase 1 Data
Tweet Send to a FriendGet Alerts RGEN Hot Sheet
Trade RGEN Now!
Repligen (Nasdaq: RGEN) shares are continuing to move higher on the session Wednesday following a release earlier showing positive data from RG3039 Phase 1 as a spinal muscular atrophy (SMA) treatment. Shares are up 8 percent on the session following the release.
From the release: "The Phase 1 trial was a blinded, ascending, single dose study of RG3039 administered to 32 healthy volunteers. The study results demonstrate that RG3039 was well tolerated at all doses administered, with no serious adverse events reported."
For more color, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
From the release: "The Phase 1 trial was a blinded, ascending, single dose study of RG3039 administered to 32 healthy volunteers. The study results demonstrate that RG3039 was well tolerated at all doses administered, with no serious adverse events reported."
For more color, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- Bulls and Bears Do Battle in Aeropostale (ARO); Turnaround Intact?
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
